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Comments on "Trouble in
Paradise"
There are statements I wish to protest in the
Focus article "Trouble in Paradise" byJohn
F. Lauerman published in Environmental
Health Perspectives [105:914-917 (1997)].
These statements appear to have been
attributed to me, but I can assure you I
would neverhave made them.
First, there is the suggestion that I
included atrazine among alist ofagricultur-
al chemicals used in pineapple cultivation.
To my knowledge, atrazine was never used
on pineapple fields. It does appear in
Hawaiian groundwater, however, as a result
ofwidespread use on sugar cane fields.
Second, I would never say that "none
of these chemicals have been conclusively
linked to adverse health effects," as the
article appears to paraphrase me having
said. I believe that scientific studies conclu-
sively link all these chemicals, and still
more, with harmful health effects in
exposed populations. What I recall having
said to Lauerman is that it is almost impos-
sible to link, with any confidence, the can-
cer or other health problem of a given
individual with exposure to pesticides.
Thus, although a population may experi-
ence an increase in cancers or other health
problems in the aggregate, the likelihood
of a person with a cancer being able to
prove to the satisfaction of a court of law
that his or her disease was the result of
exposure to a chemical is vanishinglysmall.
The state of Hawaii has very serious
contamination problems as a result of the
application of agricultural chemicals and
other pesticide products. I do not wish to
have my statements be interpreted in any
way as minimizing this problem or my own
concern for thehealth risks that this poses.
Patricia Tummons
Environment Hawaii
Hilo, Hawaii
Note: Atrazine was mistakenly included in
the list ofagricultural chemicals used in
pineapple cultivation. EHP regrets theerror.
The o2u-Globulin Discussion
One ofthe most valuable things to emerge
from the recent series ofletters published in
EHPin connection with the proposed a2u-
globulin mechanism of male rat renal car-
cinogenesis was the title ofthe final letter in
the series by Melnick et al. (1)-"Weight of
Evidence Versus Weight of Speculation to
Evaluate the Hypothesis." This arresting
tidle made me realize, for the first time, that
evidence and speculation are usually
irretrievably confused in the Discussion sec-
tion of most papers, certainly in most of
mine. It would be useful ifall papers had a
formal discussion ofthe data presented, fol-
lowed by a separate section titled
"Speculative Significance of the Data."
When an issue assumes an importance in its
own right, as with the a2u-globulin contro-
versy, the way forward should be to list the
evidence for and against the hypothesis,
leading, in turn, to an estimate ofits likely
validity. Weak points in the hypothesis
would thereby be revealed, and these could
become the focus of further experiments;
alternatively, the hypothesis could be aban-
doned. This pathwas nottaken in the recent
debate and, as aconsequence, weareleftwith
opposingspeculations andno resolution.
I tookpart in the EPAreviewoftheax2u-
globulin mechanism referred to by several of
thediscussants in thisdebate, and mostofthe
data recendy discussed were reviewed at that
time. However, thetrend inthat meetingwas
to hear the opposing arguments and to then
drawacondusion-infact, speculations were
weighed, and the balance happened to come
out in favor ofthe probable validity of the
hypothesis. Whatwas missingfrom that exer-
cise was a dissection ofeach ofthe compo-
nentdatasets, leadingto adecision as to their
individual validity. That process was started
duringthecourseoftheEHPdebate.
The a2u-globulin mechanism of renal
carcinogenesis is among the richest in data
and speculation of all proposed nongeno-
toxic mechanisms ofrodent carcinogenesis.
It is therefore critical that advantage is taken
of the impetus provided by the recent
debate and that this hypothesis is reevaluat-
ed according to rigorous scientific criteria.
Apart from the obvious need to advance our
understanding ofthe potential carcinogenic
hazard implicit in this mechanism, there is
the subsidiary question ofwhether an agent
such as limonene is formally required to be
active in the TgAC and the p53 mouse
abbreviated carcinogenicity bioassays. As
things stand at the moment (2), a positive
result in both of these assays would define
limonene as a genotoxic carcinogen, where-
as a positive result in only the TgAC skin
painting assaywould define it as a nongeno-
toxic carcinogen. A negative result in both
assays would probably be rationalized along
the lines that limonene represents the type
of nongenotoxic carcinogen that modern
methods should not be required to detect,
i.e., that it should be classified as 'generally
regarded as safe" (2). In fact, the suggested
need for such abbreviated carcinogenicity
bioassays oflimonene would probably flow
from a full analysis of the a2u-globulin
hypothesis, but that, in turn, would imply
that these two assays are already confirmed
as giving mechanistically diagnostic data,
which theyare not. Thus, the importance of
resolving thea2u-globulin debate.
Science proceeds by way of informed
speculation. However, such speculations
should not become personal property to
defend at all costs. Rather, they should be
vigorously challenged with the aim ofeither
refuting them or transforming them into
generally accepted facts. The sooner that
happens with the speculations surrounding
the ax2u-globulin hypothesis, the better.
JohnAshby
Zeneca CTL
Alderley Park
Cheshire, United Kingdom
REFERENCES
1. Melnick RL, Kohn MC, Huff J. Weight of evidence
versus weight of speculation to evaluate the a2u-
globulin hypothesis. Environ Health Perspect
105:904-906(1997).
2. Tennant RW, French JE, Spalding JW. Identifying
chemical carcinogens and assessing potential risk
in short-term bioassays using transgenic mouse
models. Environ Health Perspect 103: 942-950(1995).
Re: "A Pilot Study of Urinary
Estrogen Metabolites
(16cz-OHE1 and 2-OHE1) in
Postmenopausal Women with
and without Breast Cancer"
Ursinetal. (1) reportdataontheabsenceofa
difference in the 2-hydroxyestrone/l6a-
hydroxyestrone (2-OHE1/16a-OHE1) ratio
between breast cancer cases and controls.
These findings contrast with pilot data
recendy reported by Kabat et al. (2), indicat-
ingastrongandstatisticallysignificant inverse
association ofthe ratio with postmenopausal
breast cancer, as well as in other recently
reported studies (3). There are a number of
methodological aspects ofthe study by Ursin
etal. (1) thatrequirecomment.
First, although it is not explicitly stated,
the authors recontacted women who partic-
ipated in an earlier case-control study of
breast cancer (4) to obtain urine samples
from those qualified survivors who agreed
to participate. The cases had been diag-
nosed between March 1987 and December
1989 and were recontacted approximately
7 years later. In the original population-
based study, 1,510 matched case-control
pairs were interviewed. Only stage I and II
cases were included in that study. For the
urinary estrogen study, the authors estimat-
ed that 55-60% ofthe original participants
were excluded because they were receiving
chemotherapy or other medication or
weighed more than 200 pounds, which
might affect estrogen metabolism.
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Second, the authors excluded patients
with advanced breast cancer because ofthe
significant mortality in this group.
Third, the authors argued that exdusion
ofwomen with specific exposures is unlikely
to have introducedbias. However, weare not
told how many of the original study group
were successfully contacted, what proportion
had died, and what proportion of those
recontacted, and eligible, agreed to partici-
pate in the second study. Did these propor-
tions differbetween cases and controls?
Fourth, in addition to the possibility of
selection bias due to differential recruitment
in the second study, the lack ofa significant
difference between cases and controls may
be due to the restriction of the study to
early stage cancer. In the study by Kabat et
al. (2), among postmenopausal women the
ratio of2-OHE1/16a-OHE1 was strongly
and inversely associated with breast cancer.
However, this association was driven pri-
marily by a strong association with later
stage cancer (stages III and IV).
Finally, in the small sample forwhich the
results were reported, adjustment for breast
cancerriskfactors (indudingageatmenarche,
age atfirst pregnancy, parity, familyhistoryof
breast cancer, and ethnicity) was apparently
not carried out. This is critical because the
matched-pair design ofthe original studywas
notmaintained in thecurrentstudy.
We look forward to the full report,
which will hopefully provide more detailed
information on these questions. It should be
clearly understood that these results, as they
now stand, are in no way inconsistent with
our hypothesis that the metabolite ratio is a
valid biochemical marker forbreast cancer.
H. Leon Bradlow
Strang Cancer Research Laboratory
NewYork, NewYork
Geoffery C. Kabat
Department ofPreventive Medicine
University Medical Center
State University ofNewYork
at Stony Brook
StonyBrook, NewYork
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Response
Our pilot study (1) did not confirm
Bradlow et al.'s hypothesis of an inverse
association between the urinary ratio 2-
OHE1l16a-OHE1 and breast cancer risk.
Kabat and Bradlow raise a number ofissues
that they believe might pose problems in
ourstudy. We examine them in the order in
which theywere raised.
Bradlowand Kabat note thatweexcluded
approximately 55-60% ofparticipants in the
original study. As we explicitly state in our
description ofourpilot study (1), we contact-
edwomenwhohadparticipated in aprevious
case-control study at our institution. For the
current study, we only contacted women
with early stage (< stage II) cancers. This was
out ofconcern that the levels of the urinary
metabolites might be altered by the disease in
later stage patients and that any association
would be the result ofthe disease rather than
the cause of it. We also had a number of
exclusion criteria that applied both to cases
and to controls. We excluded cases and con-
trols who were current smokers, who were
obese, or who had recently used chemothera-
py, had anesthesia, orhad used other medica-
tions that could interfere with estrogen
metabolism. We agree that this might limit
the generalizability of the findings, but it
should not result in selection bias because the
criteriawereapplied equally to both cases and
controls. These restrictions were essential
because of concern that these factors could
influence urinary metabolite levels and thus
produce a noncausal association between the
ratio of2-OHEI to 16a-OHE1 anddisease.
In our pilot study publication, we pro-
vided the data for the first 25 cases and 23
controls we studied. We did not provide the
participation rates/exclusion rates in each
group at that time since the data collection
was ongoing, so thesample in ourpilotstudy
should be regarded as a convenience sample.
Further information will be provided in the
full study, whichwill becompletedshortly.
Kabat et al. (2) provided no information
onchoice ofcases andcontrols. In theirstudy,
cases were 4 times as likely as controls to cur-
rently use alcohol and 3.8 times as likely to
have a chronic condition (such as hyperten-
sion, arthritis, diabetes, asthma, glaucoma,
heart disease ,and allergies); these large differ-
encessuggest that theircontrol group may not
havebeen anappropriate comparison group.
Bradlow and Kabat are concerned that
lack of adjustment for various breast cancer
risk factors would have biased our results
toward the null. Although this is possible,
their interpretation oftheir own results makes
it appear unlikely. They reported that the 2-
OHE1/16a-OHEI ratio "did not show any
consistent associations with age, race/ethnici-
ty, age at first birth, parity, body mass index,
family history of breast cancer, smoking or
alcohol intake" (2). Bradlow and Kabat give
no discussion ofwhy the confounding would
be negative. Indeed, positive confounding
would appear to be equally, and possibly
more, likely. In reality, it should be remem-
bered that most ofthe breast cancer risk fac-
tors are relatively weak and their association
with urinary metabolites would need to be
ratherstrongto influence theassociationssub-
stantively. We will evaluate all these factors as
potential confounders in ourfullstudy.
Our results are, in fact, in agreement
with those reported by Kabat et al. (2), who
also found no association between the ratio
ofurinary 2-OHE1 to 16a-OHE1 and early
stage breast cancer. As they indicate in their
letter, the association they found overall was
driven primarily by strong associations with
later stage cancer in postmenopausal
women (the same association was not found
for premenopausal women). The strong
association Kabat et al. (2) report in post-
menopausal women with advanced disease
may simply be an artifact of subgroup
analysis, a result ofthe disease process itself,
or the treatment their cases obtained. While
it would be useful ifthey attempted to eval-
uate whether treatment or some other
confounder might explain their result, in
reality, it is difficult to be certain that it did
not. For this reason, we excluded women
with advanced disease from our study.
The 2-OHE1 and 16a-OHE1 assays
reported in our studywere conducted in the
laboratory ofBradlow and colleagues at the
Strang Cornell Research Laboratory, and we
are indebted to him for this and for other
help he gave in the execution ofthe study.
Giske Ursin
Stephanie London
Malcolm C. Pike
USC/Norris Comprehensive
Cancer Center
University ofSouthern California
Los Angeles, California
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